Fitxers

686010.pdf (449.11 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2019-02

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/133837

Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1080/14737167.2019.1519399

Resum

Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...)

Matèries

Medicaments, Medicaments genèrics, Anàlisi cost-benefici, Neuropsicofarmacologia, Tractament del dolor, Ansietat

Matèries (anglès)

Drugs, Generic drugs, Cost effectiveness, Neuropsychopharmacology, Pain treatment, Anxiety

Citació

Col·leccions

Articles publicats en revistes (Economia)

Citació

SICRAS MAINAR, Antoni, et al. Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin. Expert Review of Pharmacoeconomics & Outcomes Research. 2019. Vol. 19, num. 1, pags. 45-57. ISSN 1473-7167. [consulted: 7 of September of 2026]. Available at: https://hdl.handle.net/2445/133837

Exportar metadades

JSON - METS

Compartir registre